Centessa Pharmaceuticals plc
(NASDAQ: CNTA)
|
8:00 PM UTC, 06/20/25 | |||
---|---|---|---|---|
Last: $12.43 | Change: -0.25 | %Change: -1.97% | Volume: 1,612,616 |
Open: | $ 12.87 | Volume: | 1,612,616 | |
---|---|---|---|---|
High: | $ 13.02 | Yield(%) | 0.00 | |
Low: | $ 12.30 | P/E Ratio (ttm): | n/a | |
Dividend ($): | n/a | Market Cap ($): | 1.69B | |
EPS ($) | -1.80 | Shares Out: | 133.55M |
% Price Change (last 4 weeks): | 0.48 |
---|---|
% Price Change (last 13 weeks): | -22.16 |
% Price Change (last 26 weeks): | -27.75 |
% Price Change (last 52 weeks): | 43.12 |
% Price Change (year to date): | -24.30 |
Return on Equity (%): | -73.96 |
---|---|
Return on Assets (%): | -50.05 |
Return on Invested Capital (%): | -69.43 |
Gross Profit Margin (%): | n/a |
---|---|
Net Profit Margin (%): | n/a |
Operating Profit Margin (%): | 0.00 |
|
|
50-day Moving Average: | $12.60 |
---|---|
200-day Moving Average: | $15.28 |
Avg. Daily Vol. (last 50 days): | 920,195 |
Avg. Daily Vol. (last 200 days): | 810,326 |
52-wk high: | $19.09 |
52-wk low: | $8.46 |
Bid: | $4.99 |
Ask: | $14.23 |
Centessa Pharmaceuticals Plc operates as clinical-stage pharmaceutical company, which engages in discovering and developing medicines that delivers transformational to patients. Its portfolio include preclinical to phase three uncorrelated programs spanning diseases with high unmet need across oncology, hematology, immunology, inflammation, neuroscience, and rare diseases. The company was founded on October 26, 2020 and is headquartered in Altrincham, the United Kingdom.
|
Centessa Pharmaceuticals plc
1 Ashley Road 3rd Floor Altrincham CA WA14 2DT Phone: 44.7391.789784 Fax: n/a http://centessa.com |
Earnings (1year) ($): | -1.80 |
---|---|
Annual Dividend ($): | 0.00 |
Current P/E Ratio (ttm): | n/a |
Book Value ($): | 3.03 |
Cash Flow ($): | -1.77 |
Price/Earnings (x): | n/a |
---|---|
Price/Sales (x): | n/a |
Price/Book (x): | 5.53 |
Price/Cash Flow (x): | n/a |
Quick Ratio (x): | 9.25 |
---|---|
Current Ratio (x): | 9.25 |
LT Debt/Equity (x): | 29.19 |
Total Debt/Equity (x): | 29.19 |